Drugs › alpha-Adrenergic agonist
Brand name · Brimonidine tartrate
Mirvaso: adverse event reports filed with FDA
926 reports list it as a suspect or interacting product, 2013–2025. Class: alpha-Adrenergic agonist. Also reported as Mirvaso Gel.
- 926
- reports as suspect product
- 0% of all reports · about 73 a year
- 2
- reports, 12 months to June 2026
- 6 in the 12 months before
- 21%
- marked serious by the reporter
- 50.8% across the class
- 0%
- record death among outcomes, as reported
- 0 reports · not verified by FDA
926 adverse event reports received by FDA list the brand name Mirvaso (brimonidine tartrate) as a suspect or interacting product, from October 2013 to December 2025. A further 86 reports list it only as a concomitant medication, and those are not counted in the figures on this page.
In the 12 months to June 2026, 2 reports listed it, down 67% from 6 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 73 reports a year and 0% of the 20,646,523 reports in the database, and 4% of the reports for the alpha-Adrenergic agonist class. How many people take it is not in the data, so a count is not a rate of occurrence.
Reporters most often recorded erythema (56.3%), flushing (28.2%) and condition aggravated (22.9%). A report can list several reactions, so shares add to more than 100%; 137 different terms appear across these reports. Erythema is recorded in 56.3% of these reports, a larger share than in the median alpha-Adrenergic agonist drug (0.3%).
21% of the reports are marked serious by the reporter (50.8% across the class); 0% record death among the outcomes and 2.5% record hospitalisation, as reported. 56% of the reports came from consumers, and the largest patient age group is 45 to 64 (33.6%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
Reports by month, five years
Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.
By year received
Reactions recorded in the reports
share of Mirvaso reports recording the termmedian drug in alpha-adrenergic agonist
- Erythemaskin redness56.3%521
- Flushingsudden reddening or warmth of the skin28.2%261
- Condition aggravatedthe condition being treated got worse22.9%212
- Skin burning sensationburning skin17.8%165
- Rosacea17.2%159
- Feeling hotfeeling hot14.7%136
- Rebound effect14.7%136
- Drug ineffectivethe medicine did not work as expected11.8%109
- Rash macular8.3%77
- Pruritusitching7.1%66
- Pain of skin6.6%61
- Product use issuea problem in how the product was used6.5%60
- Swelling facea swollen face6.3%58
- Burning sensationa burning feeling6%56
- Inappropriate schedule of drug administrationthe medicine was taken at the wrong times5.2%48
- Pallor5%46
- Skin irritationirritated skin4.9%45
- Rash erythematousa red rash4.8%44
- Skin warm4.6%43
- Off label useused for a purpose or in a way not on the label3.8%35
- Dry skindry skin3.6%33
- Emotional distressemotional distress3.6%33
- Rashskin rash3.6%33
- Skin exfoliationpeeling skin3.6%33
- Painpain, site not specified3.5%32
- Application site erythemaredness where the product was applied3.3%31
- Rash papular3.2%30
- Acneacne2.7%25
- Drug effect decreasedthe medicine had less effect2.6%24
- Hypersensitivityan allergic-type reaction2.6%24
Top 30 of 137 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 11 drugs in the alpha-adrenergic agonist class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Outcomes recorded
Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 23,291 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."
Patients and reporters
Patient age
Patient sex
Who reported
Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 90% of reports give the United States as the country of the event or reporter.
Reason for use recorded
| Indication as recorded (MedDRA) | Reports | Share |
|---|---|---|
| Rosacea | 648 | 70% |
| Erythema | 69 | 7.5% |
| Flushing | 10 | 1.1% |
| Acne | 2 | 0.2% |
| Erythrosis | 2 | 0.2% |
The indication field is filled in by the reporter and is often blank; shares are of all 926 reports.
In context
| Measure | Mirvaso | alpha-Adrenergic agonist | All reports |
|---|---|---|---|
| Reports as suspect product | 926 | 23,291 | 20,646,523 |
| Share of that pool | — | 4% | 0% |
| Reports, latest 12 months | 2 | — | 1,332,454 |
| Marked serious | 21% | 50.8% | 57.4% |
| Death recorded among outcomes, per 1,000 reports | 0 | 156 | 91 |
| Hospitalisation recorded, per 1,000 reports | 25 | 199 | 213 |
| Consumer-filed share | 56% | 48.1% | 45.8% |
| Top term, share of reports | Erythema 56.3% | median 0.3% | 1% |
Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Other drugs in the alpha-adrenergic agonist class
| Drug | Name type | Reports | Latest 12 months | Marked serious |
|---|---|---|---|---|
| Pseudoephedrine hydrochloride | generic | 8,381 | 1,163 | 90.4% |
| Brimonidine | generic | 4,285 | 122 | 17.7% |
| Combigan | brand | 2,940 | 49 | 23.1% |
| Alphagan P | brand | 2,656 | 110 | 31.9% |
| Brimonidine tartrate | generic | 1,012 | 178 | 42.2% |
| Claritin-D | brand | 732 | 16 | 22.5% |
| Alavert | brand | 618 | 0 | 31.6% |
| Loratadine and pseudoephedrine sulfate | generic | 616 | 22 | 10.2% |
| Midodrine hydrochloride | generic | 595 | 51 | 70.1% |
| Pseudoephedrine hcl | generic | 530 | 0 | 94.7% |
Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.
Questions about Mirvaso reports
How many adverse event reports has FDA received for Mirvaso?
926 reports list Mirvaso as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 2 of them arrived in the latest 12 months. Another 86 list it only as a concomitant medication.
What reactions are recorded in Mirvaso reports?
erythema (56.3%), flushing (28.2%), condition aggravated (22.9%), skin burning sensation (17.8%) and rosacea (17.2%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Mirvaso was responsible.
How serious are the reports?
21% are marked serious by the reporter. Among the outcomes recorded, 0% of reports include death and 2.5% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.
Who files these reports?
consumer or non-health professional (56%), not given (22.2%) and physician (12.6%). Most reports reach FDA through the manufacturer, which must forward reports it receives.
Are reports for Mirvaso rising?
2 reports in the 12 months to June 2026, down 67% from 6 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.
Do these reports show that Mirvaso was responsible for these reactions?
No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.
Is this a list of the side effects of Mirvaso?
No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.
How do I report an adverse event?
Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Mirvaso as a suspect or interacting product; reports listing it only as a concomitant medication (86) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.